Andrew Germanovich
Interventional Pain Medicine · Rancho Mirage, CANPI 1043479835
Payments from drug & device makers
Across 729 payments — averaging $560.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Masimo Corporation$393K
- Abbott$2K
- Biohaven Pharmaceuticals, Inc.$1K
- AbbVie$1K
- Medtronic$781
- Stryker$713
- plus $9K from 52 others
Across 15 payments — averaging $7366.87 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Masimo Corporation$111K
What the payments were for
- Consulting fees$7,7252%
- Speaking & faculty fees$308,65593%
- Travel & lodging$2,1901%
- Food & beverage$14,5134%
- Education$460%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SET and rainbow SET$312,042
- Patient SafetyNet System$7,254
- EMMA and ISA$2,997
- rainbow Acoustic Monitoring$2,997
- SedLine$2,997
- NURTEC ODT$1,445
- Evoke$486
- EXPAREL$382
- SPINEJACK$311
- Prometra II$278
- GENERAL PAIN MANAGEMENT$239
- BOTOX$231
- Senza Spinal Cord Stimulation System$176
- Prospera$148
- mild Device Kit$146
- Prolate$138
- Nalocet$138
- Omnia$135
- S-Series SCS Leads$133
- Proclaim Family of SCS IPGs$127
How this compares
$408,422 in reported general payments places this provider in the 95th percentile of 188 interventional pain medicine providers in California.
See all interventional pain medicine providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Diclofenac Epolamine | 13 | $7,592 |
| Pregabalin | 237 | $4,469 |
| Gabapentin | 102 | $1,687 |
| Tramadol Hcl | 196 | $1,383 |
| Celecoxib | 48 | $1,234 |
| Tizanidine Hcl | 61 | $1,078 |
| Tramadol Hcl ErTramadol Hcl | 12 | $1,049 |
| Quetiapine Fumarate | 13 | $895 |
| Methocarbamol | 62 | $689 |
| Amitriptyline Hcl | 82 | $666 |
| Mirtazapine | 24 | $648 |
| Methadone Hcl | 69 | $456 |
| Diclofenac Sodium | 25 | $420 |
| Duloxetine Hcl | 32 | $272 |
| Meloxicam | 63 | $231 |
Paid to pharmacies, not to this prescriber.
Other interventional pain medicine in Rancho Mirage
- Tim LeierRancho Mirage$749K
- Yamin SallowmRancho Mirage$16K
- Sheldon JordanSanta Monica$3.1M
- Ezekiel FinkBeverly Hills$2.3M
- Matthew DotyOroville$1.3M
- Pragya GuptaEscondido$647K
- Michael Verdolinla Mesa$563K
- Standiford HelmOrange$476K
- Patrick BuchananCamarillo$453K
- Roy BrownlowSan Diego$452K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.